-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: National, dioxin pharmaceutical industry, fumarate novove dioxin tablets, September 5, birch pharmaceutical industry issued a notice that recently received the Approval of the State Drug Administration issued a class 3 new drug fumarate novotalfoestyl tablets (0.15g, 0.2g) "drug registration certificate."
On August 21, 2020, the Company disclosed that it had obtained a registration certificate for four types of fumarate novovir diamide tablets (0.3g) for the treatment of chronic hepatitis B infections in adults and children 12 years of age and older, as well as human immunodeficiency virus type 1 (HIV-1) infections, as a first-line drug for the treatment of chronic hepatitis B.
this time obtained 3 new drugs fumarate novove dioxin ester tablets (0.15g, 0.2g) is the only domestic approval, the current domestic listed enterprises (including the original research) are 0.3g specification fumarate novove dipyrivergide tablets.
's approved 0.15g, 0.2g specification is primarily used for HIV-1 infections in adults and children aged 2 years and older and for patients with chronic hepatitis B 2 years and older and weight of 17 kg for adults and children aged 2 years and older, and is the first approved for use in children aged 2 years and older.
approved 0.15g and 0.2g specifications are evaluated consistently in accordance with existing drug registration regulations.
Fumarate novovir diamide tablets are the most powerful and effective anti-hepatitis B virus drugs in the field of liver disease treatment, there are few drug-resistant reports, can effectively reverse liver fibrosis and even cirrhosis, can significantly reduce the incidence of hepatitis B-related liver cancer, but long-term use needs to keep an eye on its side effects on the kidneys and bones.
Hepatitis B stock patients in the middle and elderly patients, prone to bone loss and osteoporosis, our 0.15g and 0.2g small dose specifications can effectively reduce its side effects without reducing efficacy, while providing the best choice for children aged 2-12 years of age safe medication.
.
